1,086 results on '"factor XIIIa"'
Search Results
2. Ethacrynic acid is an inhibitor of human factor XIIIa
- Author
-
Srabani Kar, Kayla Vu, Madhusoodanan Mottamal, and Rami A. Al-Horani
- Subjects
Ethacrynic acid ,Factor XIIIa ,Irreversible inhibitor ,Bleeding ,Anticoagulant ,Therapeutics. Pharmacology ,RM1-950 ,Toxicology. Poisons ,RA1190-1270 - Abstract
Abstract Background Ethacrynic acid (EA) is a loop diuretic that is approved orally and parenterally to manage edema-associated diseases. Nevertheless, it was earlier reported that it is also associated with bleeding upon its parenteral administration. In this report, we investigated the effects of EA on human factor XIIIa (FXIIIa) of the coagulation process using a variety of techniques. Methods A series of biochemical and computational methods have been used in this study. The potency and efficacy of human FXIIIa inhibition by EA was evaluated using a bisubstrate-based fluorescence trans-glutamination assay under near physiological conditions. To establish the physiological relevance of FXIIIa inhibition by EA, the effect on FXIIIa-mediated polymerization of fibrin(ogen) as well as the formation of fibrin(ogen) – α2-antiplasmin complex was evaluated using SDS-PAGE experiments. The selectivity profile of EA against other coagulation proteins was assessed by evaluating EA’s effect on human clotting times in the activated partial thromboplastin time (APTT) and the prothrombin time (PT) assays. We also used molecular modeling studies to put forward a putative binding mode for EA in the active site of FXIIIa. Results involving EA were the average of at least three experiments and the standard error ± 1 was provided. In determining the inhibition parameters, we used non-linear regression analysis. Results FXIIIa is a transglutaminase that works at the end of the coagulation process to form an insoluble, rigid, and cross-linked fibrin rich blood clot. In fact, inhibition of FXIIIa-mediated biological processes has been reported to result in a bleeding diathesis. Inhibition of FXIIIa by EA was investigated given the nucleophilic nature of the thiol-containing active site of the enzyme and the Michael acceptor-based electrophilicity of EA. In a bisubstrate-based fluorescence trans-glutamination assay, EA inhibited FXIIIa with a moderate potency (IC 50 ~ 105 µM) and efficacy (∆Y ~ 66%). In SDS-PAGE experiments, EA appears to significantly inhibit the FXIIIa-mediated polymerization of fibrin(ogen) as well as the formation of fibrin(ogen) – α2-antiplasmin complex which indicates that EA affects the physiological functions of FXIIIa. Interestingly, EA did not affect the clotting times of human plasma in the APTT and the PT assays at the highest concentration tested of 2.5 mM suggesting the lack of effects on the coagulation serine proteases and potentially the functional selectivity of EA with respect to the clotting process. Molecular modeling studies demonstrated that the Michael acceptor of EA forms a covalent bond with catalytic residue of Cys314 in the active site of FXIIIa. Conclusions Overall, our studies indicate that EA inhibits the physiological function of human FXIIIa in vitro which may potentially contribute to the bleeding complications that were reported with the association of the parenteral administration of EA.
- Published
- 2022
- Full Text
- View/download PDF
3. Integration of clotting and fibrinolysis: central role of platelets and factor XIIIa.
- Author
-
Patalakh I, Revka O, Gołaszewska A, Bielicka N, and Misztal T
- Subjects
- Humans, Platelet-Rich Plasma metabolism, Platelet Aggregation, Blood Platelets metabolism, Blood Coagulation, Factor XIIIa metabolism, Fibrinolysis, Fibrin metabolism, Thrombin metabolism
- Abstract
Purpose: The aim of the present study was to establish the role of platelets and activated factor XIIIa (FXIIIa) in the structuring of the fibrin network as well as to clarify the effect of network compaction on clot lysis., Methods: Turbidimetry was used for the one-stage clotting test where platelet-free plasma (PFP) is regarded as single factor-deficient plasma (platelets as lacking factor) and autologous platelet-rich plasma (PRP) as deficiency corrected plasma. Structural features of the developed and subsequently lysed fibrin network, formed under static and flow conditions, were visualized by confocal microscopy., Results: Thrombin-initiated plasma clotting revealed changes in the shape of the absorption curve, more pronounced in the presence of platelets. These changes correlate with the transformation of the fibrin scaffold during clot maturing. With the combined action of platelets, thrombin and Ca2+, plasma clotting passes through two phases: initial formation of a platelet-fibrin network (first peak in the polymerization curve), and then the compaction of fibrin, driven by FXIIIa (the second peak) which can be further modulate by the contractile action of platelets. These structural changes, mediated by platelets and FXIIIa, have been shown to determine subsequent clot lysis., Conclusions: Platelet aggregates serve as organizing centers that determine the distribution of fibrin in clot volume. The openwork structure of the platelet-transformed fibrin provides the necessary prerequisites for its timely lysis. The revealed aspects of the interaction of platelets and FXIIIa, which accompanies the maturation of a fibrin clot, may lead to new approaches in the pharmacological correction of disorders associated with both thrombotic episodes and bleeding tendency., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Ethacrynic acid is an inhibitor of human factor XIIIa.
- Author
-
Kar, Srabani, Vu, Kayla, Mottamal, Madhusoodanan, and Al-Horani, Rami A.
- Subjects
BLOOD coagulation ,FIBRIN ,PARTIAL thromboplastin time ,BINDING sites ,SERINE proteinases ,NONLINEAR regression - Abstract
Background: Ethacrynic acid (EA) is a loop diuretic that is approved orally and parenterally to manage edema-associated diseases. Nevertheless, it was earlier reported that it is also associated with bleeding upon its parenteral administration. In this report, we investigated the effects of EA on human factor XIIIa (FXIIIa) of the coagulation process using a variety of techniques. Methods: A series of biochemical and computational methods have been used in this study. The potency and efficacy of human FXIIIa inhibition by EA was evaluated using a bisubstrate-based fluorescence trans-glutamination assay under near physiological conditions. To establish the physiological relevance of FXIIIa inhibition by EA, the effect on FXIIIa-mediated polymerization of fibrin(ogen) as well as the formation of fibrin(ogen) – α
2 -antiplasmin complex was evaluated using SDS-PAGE experiments. The selectivity profile of EA against other coagulation proteins was assessed by evaluating EA's effect on human clotting times in the activated partial thromboplastin time (APTT) and the prothrombin time (PT) assays. We also used molecular modeling studies to put forward a putative binding mode for EA in the active site of FXIIIa. Results involving EA were the average of at least three experiments and the standard error ± 1 was provided. In determining the inhibition parameters, we used non-linear regression analysis. Results: FXIIIa is a transglutaminase that works at the end of the coagulation process to form an insoluble, rigid, and cross-linked fibrin rich blood clot. In fact, inhibition of FXIIIa-mediated biological processes has been reported to result in a bleeding diathesis. Inhibition of FXIIIa by EA was investigated given the nucleophilic nature of the thiol-containing active site of the enzyme and the Michael acceptor-based electrophilicity of EA. In a bisubstrate-based fluorescence trans-glutamination assay, EA inhibited FXIIIa with a moderate potency (IC50 ~ 105 µM) and efficacy (∆Y ~ 66%). In SDS-PAGE experiments, EA appears to significantly inhibit the FXIIIa-mediated polymerization of fibrin(ogen) as well as the formation of fibrin(ogen) – α2 -antiplasmin complex which indicates that EA affects the physiological functions of FXIIIa. Interestingly, EA did not affect the clotting times of human plasma in the APTT and the PT assays at the highest concentration tested of 2.5 mM suggesting the lack of effects on the coagulation serine proteases and potentially the functional selectivity of EA with respect to the clotting process. Molecular modeling studies demonstrated that the Michael acceptor of EA forms a covalent bond with catalytic residue of Cys314 in the active site of FXIIIa. Conclusions: Overall, our studies indicate that EA inhibits the physiological function of human FXIIIa in vitro which may potentially contribute to the bleeding complications that were reported with the association of the parenteral administration of EA. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. Reports from National Academy of Sciences of UKraine Add New Data to Findings in Fibrinolysis (Integration of Clotting and Fibrinolysis: Central Role of Platelets and Factor Xiiia).
- Subjects
BLOOD coagulation factors ,BLOOD proteins ,PLATELET-rich plasma ,LIFE sciences ,COENZYMES - Abstract
Researchers from the National Academy of Sciences of Ukraine have conducted a study on the integration of clotting and fibrinolysis, focusing on the central role of platelets and Factor XIIIa in the process. The study utilized turbidimetry and confocal microscopy to visualize structural changes in the fibrin network during clot formation and lysis. The findings suggest that platelets and Factor XIIIa play crucial roles in determining the subsequent clot lysis, which may have implications for pharmacological interventions in thrombotic and bleeding disorders. For more information, readers can refer to the Bioscience Reports journal article by contacting the National Academy of Sciences of Ukraine. [Extracted from the article]
- Published
- 2024
6. Thromboelastographic study of fibrin clot and molecular basis of maximum clot firmness
- Author
-
D. S. Korolova, Y. M. Stohnii, V. I. Gryshchuk, S. I. Zhuk, I. V. Us, T. M. Chernyshenko, O. P. Kostiuchenko, K. P. Klymenko, O. M. Platonov, O. I. Ivashchenko, and V. O. Chernyshenko
- Subjects
factor xiiia ,fibrinogen ,maximum clot firmness ,thromboelastography ,thrombosis ,Biochemistry ,QD415-436 ,Medicine ,Biology (General) ,QH301-705.5 - Abstract
Maximum clot firmness (MCF) is the main parameter of thromboelastography (TEG) reflecting the stability of a clot. In this work, we looked for markers that can influence the enhancement of MCF and detected molecular markers and blood clotting parameters that can be involved in such mechanisms. Blood samples of pregnant women with placental disorders were collected in the Kyiv Perinatal Center. TEG was performed on whole blood in EXTEM and INTEM tests. APTT, INR, fibrinogen concentration and platelet aggregation were measured using traditional laboratory approaches. D-dimer was detected in sandwich ELISA using monoclonal antibodies III-3B and II-4D. The relative cross-linking activity of factor XIIIa was measured by the direct quantification of the cross-linked γ-chain of fibrin using Western-Blotting with monoclonal antibody II-4D. D-dimer and fibrinogen concentrations, clotting time in the APTT test, INR and rate of platelet aggregation did not correlate with the MCF. However, we found positive correlations of MCF with factor XIIIa activity: 0.51 and 0.87 for EXTEM and INTEM, respectively. These data indicate that for normal and slightly increased fibrinogen concentrations, fibrin clot firmness will depend mostly on the activity of factor XIIIa. Thus the direct determination of factor XIIIa activity in blood plasma of patients can be relevant for predicting the risk of intravascular coagulation. Evaluation of the content and activity of individual clotting factors or other components of the coagulation system can be useful additions to the TEG diagnostics and should not be neglected.
- Published
- 2021
- Full Text
- View/download PDF
7. A Congenital Oval Plaque
- Author
-
El-Darouti, Mohammad Ali, Al-Ali, Faiza Mohamed, El-Darouti, Mohammad Ali, and Al-Ali, Faiza Mohamed
- Published
- 2019
- Full Text
- View/download PDF
8. Hybrid Photopatterned Enzymatic Reaction (HyPER) for in Situ Cell Manipulation
- Author
-
Griffin, Donald R, Borrajo, Jacob, Soon, Allyson, Acosta‐Vélez, Giovanny F, Oshita, Victor, Darling, Nicole, Mack, Julia, Barker, Thomas, Iruela‐Arispe, M Luisa, and Segura, Tatiana
- Subjects
Bioengineering ,Biotechnology ,Generic health relevance ,Amino Acid Sequence ,Biocatalysis ,Enzymes ,Immobilized ,Extracellular Matrix ,Factor XIIIa ,Human Umbilical Vein Endothelial Cells ,Humans ,Hydrogels ,Light ,Oligopeptides ,enzyme catalysis ,factor XIIIa ,hydrogels ,nitrobenzene ,photochemistry ,Medicinal and Biomolecular Chemistry ,Biochemistry and Cell Biology ,Organic Chemistry - Abstract
The ability to design artificial extracellular matrices as cell-instructive scaffolds has opened the door to technologies capable of studying the fate of cells in vitro and to guiding tissue repair in vivo. One main component of the design of artificial extracellular matrices is the incorporation of biochemical cues to guide cell phenotype and multicellular organization. The extracellular matrix (ECM) is composed of a heterogeneous mixture of proteins that present a variety of spatially discrete signals to residing cell populations. In contrast, most engineered ECMs do not mimic this heterogeneity. In recent years, photo-deprotection has been used to spatially immobilize signals. However, this approach has been limited mostly to small peptides. Here we combine photo-deprotection with enzymatic reaction to achieve spatially controlled immobilization of active bioactive signals that range from small molecules to large proteins. A peptide substrate for transglutaminase factor XIII (FXIIIa) was caged with a photo-deprotectable group, which was then immobilized to the bulk of a cell-compatible hydrogel. With focused light, the substrate can be deprotected and used to immobilize patterned bioactive signals. This approach offers an innovative strategy to immobilize delicate bioactive signals, such as growth factors, without loss of activity and enables in situ cell manipulation of encapsulated cells.
- Published
- 2014
9. Immunohistochemical analysis of chronic and recurrent dermatophytosis.
- Author
-
Bhat RM, Madhumita M, Marla NJ, and Jayaraman J
- Subjects
- Humans, Langerhans Cells, Epidermis, Factor XIIIa, Skin pathology, Tinea pathology
- Abstract
Background: Dermatophytosis has assumed epidemic proportions with rising resistance, recalcitrance and recurrence, especially in tropical regions. While various factors contribute to high prevalence worldwide, yet little is known about the interactions between host defence mechanisms and dermatophytes, particularly in chronic and recalcitrant dermatophytosis., Objectives: We aimed to compare the population of various immune cells in specimens of chronic recurrent dermatophytosis and those with acute superficial dermatophytosis., Methods: We investigated the density of various immune cells-Langerhans cells (CD1a+), macrophages (CD68+), dermal dendrocytes (Factor XIIIa+) in the skin of chronic dermatophytosis patients and those with successfully resolved lesions (controls)., Results: Langerhans cells were significantly decreased in the epidermis of patients, both in affected and unaffected areas in comparison with controls. In the dermis, however, no differences in the density of immune cells (macrophages and fibroblasts) were observed., Limitations: The limited sample size and immune cells evaluated could be expanded further in future research., Conclusion: These results indicate that the decreased number of Langerhans cells could be a potential risk factor for the development of chronic and recurrent dermatophytosis., (© 2024 Wiley-VCH GmbH. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
10. Patient-centered approach to managing factor XIII deficiency
- Author
-
Varun Iyengar, Salley Pels, and Caitlin Montcrieff
- Subjects
medicine.medical_specialty ,Factor XIII ,business.industry ,General Medicine ,Disease ,Clot formation ,medicine.disease ,Factor XIII Deficiency ,Recombinant Proteins ,Patient-Centered Care ,medicine ,Humans ,Factor XIII deficiency ,Dosing ,Intensive care medicine ,business ,Factor XIIIa ,medicine.drug ,Patient centered - Abstract
Factor XIII (FXIII) is a thrombin-activated protransglutaminase that plays a key role in blood clot formation. Congenital FXIII A-subunit deficiency represents a rare bleeding disorder that affects one in 2–3 million individuals worldwide and is treated with recombinant FXIII (rFXIII). However, due to the rarity of the disease, clinicians are often left to weigh individual variation in FXIII activity and/or symptoms to optimally guide dosing. Cases often become further complicated when patients experience refractory bleeding, which can be difficult to treat. This report describes an approach to rFXIII dosing in two patients who required deviation from standard protocols to maintain therapeutic FXIII troughs. We highlight limitations in our understanding of FXIII deficiency management, while also providing an example of the application of pharmacokinetic data to individualise therapy for improved outcomes. Finally, the case reminds us of the importance of patient-centered, cost-conscious care and multidisplinary teamwork in complex cases.
- Published
- 2023
11. D-dimer: A Marker of Severity in COVID-19
- Author
-
B Saravanan, S Vasuki, BM Pabithadevi, M Saradha, R Raskin Erusan, S Alagesan, and Shantaraman Kalyanaraman
- Subjects
endothelial dysfunction ,factor xiiia ,fibrinogen ,severity ,Medicine - Abstract
Introduction: The ever-growing number of COVID-19 patients stresses upon the need to identify effective yet readily available predictors of disease severity to ensure better clinical outcomes. D-dimer is a fibrin specific degradation product derived by enzymatic action of plasmin on factor XIIIa cross-linked fibrin. It serves as an ideal marker for activation of coagulation and fibrinolytic pathways. Identification of coagulopathy as an important complication in COVID-19 patients has brought to focus D-dimer as a possible predictor of clinical severity in patients. Aim: In this study, we analysed the role of D-dimer levels in assessing the clinical severity of the COVID-19 patients. Materials and Methods: We enrolled 217 in-patients of Tirunelveli Medical College in this single centre observational study and classified them into asymptomatic, mild, moderate and severe according to “Clinical Management Protocol: COVID 19”, by the Ministry of Health and Family Welfare and Director General of Health Services. D-dimer was estimated in the separated plasma, using latex based assay using semi-automated coagulation analyser. Data were presented as percentages for categorical variables and median±Inter Quartile Range (IQR) for continuous variables. Chi-square test was used to compare the D-dimer values between symptomatic and asymptomatic groups. A value of p
- Published
- 2020
- Full Text
- View/download PDF
12. D-dimer: A Marker of Severity in COVID-19.
- Author
-
SARAVANAN, B., VASUKI, S., PABITHADEVI, BM., SARADHA, M., RASKIN ERUSAN, R., ALAGESAN, S., and KALYANARAMAN, SHANTARAMAN
- Subjects
- *
FIBRIN fibrinogen degradation products , *FIBRIN fragment D , *COVID-19 , *TREATMENT effectiveness , *MEDICAL care - Abstract
Introduction: The ever-growing number of COVID-19 patients stresses upon the need to identify effective yet readily available predictors of disease severity to ensure better clinical outcomes. D-dimer is a fibrin specific degradation product derived by enzymatic action of plasmin on factor XIIIa cross-linked fibrin. It serves as an ideal marker for activation of coagulation and fibrinolytic pathways. Identification of coagulopathy as an important complication in COVID-19 patients has brought to focus D-dimer as a possible predictor of clinical severity in patients. Aim: In this study, we analysed the role of D-dimer levels in assessing the clinical severity of the COVID-19 patients. Materials and Methods: We enrolled 217 in-patients of Tirunelveli Medical College in this single centre observational study and classified them into asymptomatic, mild, moderate and severe according to “Clinical Management Protocol: COVID 19”, by the Ministry of Health and Family Welfare and Director General of Health Services. D-dimer was estimated in the separated plasma, using latex based assay using semi-automated coagulation analyser. Data were presented as percentages for categorical variables and median±Inter Quartile Range (IQR) for continuous variables. Chi-square test was used to compare the D-dimer values between symptomatic and asymptomatic groups. A value of p<0.05 was considered statistically significant. Results: Among the 217 cases, 88.9% were asymptomatic cases, 8.8% presented with mild clinical severity and 2.3% had moderate clinical presentation. In our study population, the Mean±SD and Median±IQR of D-dimer values (in ng/mL) were 223.4±230.6 and 157.0±187.7, respectively. The mean D-dimer value was found to increase as the category of our study group ascended from asymptomatic patients to mild and moderate clinical cases. It was noted that 91.1% of the cases who had D-dimer values <500 ng/mL were asymptomatic. Also, the odds of patients with high levels of D-dimer being clinically symptomatic was 5.5 times more than the odds of patients with D-dimer levels <500 ng/mL. Conclusion: Elevation of D-dimer levels associated with the severity of clinical course of patients infected with SARS CoV-2 when compared to patients with mild or asymptomatic clinical presentations. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Ulcerated cellular benign fibrous histiocytoma: A challenging diagnosis in biopsy practice.
- Author
-
Bartoš, Vladimír
- Subjects
- *
DERMATOFIBROMA , *SKIN tumors , *OLDER women , *BIOPSY , *CELL growth - Abstract
A biopsy diagnosis of conventional (common) type of benign fibrous histiocytoma (BFH) is usually easy. However, there are many other histopathologic variants, that may cause difficulties to make an accurate diagnosis. The author describes a 53-year old women, who presented with a protuberated ulcerated skin tumor arising on the left shoulder. It consisted of a highly cellular mass of proliferating spindle-shaped cells with a fascicular growth pattern, that was confined to dermis. The cells were relatively uniform with a slightly increased mitotic rate and proliferation activity. Immunohistochemically, the tumor expressed vimentin, Factor XIIIa and alpha-SMA, while it was negative for CK5/6, CK7, BerEP4, p63, EMA, S-100, melan A, HMB-45, MSA, h-caldesmon and CD34. A diagnosis of ulcerated cellular BFH was made. Although BFH is a very frequent cutaneous tumor, its less common cellular variant may result in diagnostic pitfalls. The purpose of this paper was to point out that even such „banal" and prognostically favourable cutaneous lesion sometimes requires a complex differential diagnostic approach in biopsy practice. [ABSTRACT FROM AUTHOR]
- Published
- 2020
14. Mass Spectrometric Identification of a Novel Factor XIIIa Cross-Linking Site in Fibrinogen
- Author
-
Mariya E. Semkova and J. Justin Hsuan
- Subjects
transglutaminases ,factor XIIIa ,transglutaminase cross-linking ,mass spectrometry ,fibrinogen ,Microbiology ,QR1-502 - Abstract
Transglutaminases are a class of enzymes that catalyze the formation of a protein:protein cross-link between a lysine and a glutamine residue. These cross-links play important roles in diverse biological processes. Analysis of cross-linking sites in target proteins is required to elucidate their molecular action on target protein function and the molecular specificity of different transglutaminase isozymes. Mass-spectrometry using settings designed for linear peptide analysis and software designed for the analysis of disulfide bridges and chemical cross-links have previously been employed to identify transglutaminase cross-linking sites in proteins. As no control peptide with which to assess and improve the mass spectrometric analysis of TG cross-linked proteins was available, we developed a method for the enzymatic synthesis of a well-defined transglutaminase cross-linked peptide pair that mimics a predicted tryptic digestion product of collagen I. We then used this model peptide to determine optimal score thresholds for correct peptide identification from y- and b-ion series of fragments produced by collision-induced dissociation. We employed these settings in an analysis of fibrinogen cross-linked by the transglutaminase Factor XIIIa. This approach resulted in identification of a novel cross-linked peptide in the gamma subunit. We discuss the difference in behavior of ions derived from different cross-linked peptide sequences and the consequent demand for a more tailored mass spectrometry approach for cross-linked peptide identification compared to that routinely used for linear peptide analysis.
- Published
- 2021
- Full Text
- View/download PDF
15. Skin
- Author
-
Ferringer, Tammie, Lin, Fan, editor, and Prichard, Jeffrey, editor
- Published
- 2015
- Full Text
- View/download PDF
16. Linking inflammation and angiogenesis with fibrogenesis: Expression of FXIIIA, MMP-9, and VEGF in oral submucous fibrosis.
- Author
-
Choudhari S, Kulkarni D, Patankar S, Kheur S, and Sarode S
- Subjects
- Humans, Angiogenesis, Fibrosis, Vascular Endothelial Growth Factor A, Factor XIIIa, Matrix Metalloproteinase 9, Oral Submucous Fibrosis
- Abstract
Objectives: Interplay of Factor XIIIa (FXIIIa), a transglutaminase, responsible for cross-linking of matrix proteins, Matrix Metalloproteinase-9 (MMP-9), a gelatinase, and Vascular Endothelial Growth Factor (VEGF), an angiogenic inducer, were studied in relation to fibrogenesis and disease progression in oral submucous fibrosis (OSMF)., Material and Methods: Immunohistochemical expression of markers was studied in 60 formalin-fixed paraffin-embedded tissue blocks of OSMF and 20 normal oral mucosal tissues. FXIIIa was studied quantitatively while MMP-9 and VEGF were assessed semi-quantitatively. Expression was compared with histopathological grades of OSMF., Results: FXIIIa expression significantly increased in OSMF (p-value 0.000). However, expression decreased and cells became quiescent with increasing grades (p-value 0.000). MMP-9 (p-value epithelium 0.011, p-value connective tissue 0.000) and VEGF expression (p-value epithelium 0.000, connective tissue 0.000) increased in OSMF. A negative correlation between FXIIIa and MMP-9 (-0.653) in early grade (p-value of 0.021) and a positive correlation between FXIIIa and VEGF (0.595) (p-value of 0.032) was found in the moderate grade OSMF. Regression analysis showed a significant association (p<0.01) of FXIIIa in OSMF and with increasing grades of OSMF., Conclusion: FXIIIa may play a crucial role in initiation of fibrosis in OSMF. MMP-9 may have a diverse role to play in OSMF as a regulator of fibrosis. VEGF may show an angio-fibrotic switch and contribute to fibrosis in OSMF. These cytokines may show altered function and can contribute to fibrosis and chronicity of disease due to changes in the microenvironment. Tissue stiffness in OSMF itself creates an environment that enhances the chronicity of the disease., (Copyright © 2023 Sociedad Española de Anatomía Patológica. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. Hypocellular medallion‐like dermal dendrocyte hamartoma on the abdomen of a 25 year old male.
- Author
-
Porubsky, Caitlin F., Combs, Angela, Buckley, Christopher, and Goodman, Marcus B.
- Subjects
- *
HAMARTOMA , *MESENCHYMAL stem cells , *DERMATOFIBROSARCOMA , *GENE expression , *NEVUS - Abstract
Medallion‐like dermal dendrocyte hamartoma is a rare congenital lesion that is more commonly seen in females. It often presents at birth on the neck or upper trunk as a well‐circumscribed, atrophic patch with wrinkling of the overlying skin. Clinically, the differential diagnosis includes atrophoderma, anetoderma, and congenital atrophic dermatofibrosarcoma protuberans. Histologic findings show epidermal atrophy and dermal spindle cell proliferation that is CD34 positive, along with Factor XIIIa in the original reports. Due to this CD34 positivity, another name for the lesion is plaque‐like CD34+ dermal fibroma. We present a unique patient case as he is male and the lesion is located on his abdomen. Further reports and studies need to be done for thorough understanding of this neoplasm. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Reports from University of Pennsylvania Add New Data to Findings in Factor XIIIa (Fluorescent Peptide for Detecting Factor Xiiia Activity and Fibrin In Whole Blood Clots Forming Under Flow).
- Subjects
PEPTIDES ,THROMBOSIS ,BLOOD coagulation ,FIBRIN ,BLOOD coagulation factors ,FIBRIN tissue adhesive ,BLOOD proteins - Abstract
A recent study conducted at the University of Pennsylvania explored the use of a fluorescent peptide to detect Factor XIIIa activity and fibrin in whole blood clots forming under flow. The researchers aimed to monitor fibrin formation and crosslinking within fibrin structures in whole blood clots. The study found that the synthetic peptide provided strong and sustained labeling of fibrin as it formed under flow. This research contributes to the understanding of clotting mechanisms and may have implications for monitoring and visualizing fibrin formation in various medical contexts. [Extracted from the article]
- Published
- 2024
19. Why fibrin biomechanical properties matter for hemostasis and thrombosis
- Author
-
Tímea Feller, Robert A.S. Ariёns, and Simon D. Connell
- Subjects
Fibrin ,Hemostasis ,Future studies ,biology ,Atomic force microscopy ,Chemistry ,Force spectroscopy ,Thrombosis ,Hematology ,medicine.disease ,Elasticity ,Thromboembolism ,medicine ,biology.protein ,Humans ,Activated factor XIII ,Thromboembolic disease ,Factor XIIIa ,Biomedical engineering - Abstract
Polymeric fibrin displays unique structural and biomechanical properties that contribute to its essential role of generating blood clots that stem bleeds. The aim of this review is to discuss how the fibrin clot is formed, how protofibrils make up individual fibrin fibers, what the relationship is between the molecular structure and fibrin biomechanical properties, and how fibrin biomechanical properties relate to the risk of thromboembolic disease. Fibrin polymerization is driven by different types of bonds, including knob-hole interactions displaying catch-slip characteristics, and covalent crosslinking of fibrin polypeptides by activated factor XIII. Key biophysical properties of fibrin polymer are its visco-elasticity, extensibility and resistance to rupture. The internal packing of protofibrils within fibers changes fibrin biomechanical behavior. There are several methods to analyze fibrin biomechanical properties at different scales, including AFM force spectroscopy, magnetic or optical tweezers and rheometry, amongst others. Clinically, fibrin biomechanical characteristics are key for the prevention of thromboembolic disorders such as pulmonary embolism. Future studies are needed to address unanswered questions regarding internal molecular structure of the fibrin polymer, the structural and molecular basis of its remarkable mechanical properties and the relationship of fibrin biomechanical characteristics with thromboembolism in patients with deep vein thrombosis and ischemic stroke.
- Published
- 2022
20. CD68-negative nonlipidized juvenile xanthogranuloma
- Author
-
Tzu-Kun Lo, Kung-Chao Chang, Chia-Bao Chu, and Julia Yu-Yun Lee
- Subjects
CD163 ,CD68 ,factor XIIIa ,nonlipidized juvenile xanthogranuloma ,Touton giant cell ,Dermatology ,RL1-803 - Abstract
Juvenile xanthogranuloma (JXG) belongs to the group of non-Langerhans cell histiocytosis. JXG is typically factor XIIIa- and CD68-positive. Nonlipidized JXG (NJXG) is a rare, mononuclear variant of JXG that shows few or absence of foam cells or Touton giant cells in the histiocytic infiltrate. Herein, we describe an unusual case of NJXG in a 7-year-old boy presenting with a 1-month history of a flesh-colored nodule on the forehead. The lesion was factor XIIIa-positive and CD68-negative but CD163-positive. Our case illustrates that CD163, a more specific marker of macrophage and monocyte differentiation, is a valuable marker for the diagnosis of NJXG.
- Published
- 2017
- Full Text
- View/download PDF
21. Factor XIIIA Induction in the Retina and Optic Nerve After Optic Nerve Lesion in Goldfish
- Author
-
Sugitani, Kayo, Oogai, Kazuhiro, Nakashima, Hiroshi, Kato, Satoru, LaVail, Matthew M., editor, Ash, John D., editor, Anderson, Robert E., editor, Hollyfield, Joe G., editor, and Grimm, Christian, editor
- Published
- 2012
- Full Text
- View/download PDF
22. A Case of Cellular Fibrous Histiocytoma on the Right Elbow with Repeated Relapse within a Short Period
- Author
-
Kanako Tsunoda, Hiroki Oikawa, Fumihiko Maeda, Kazuhiro Takahashi, and Toshihide Akasaka
- Subjects
CD34 ,CD163 ,CD44 ,Cellular fibrous histiocytoma ,Dermatofibrosarcoma protuberans ,Factor XIIIa ,Dermatology ,RL1-803 - Abstract
Cellular fibrous histiocytoma, a variant of fibrous histiocytoma, is a designation used for lesions showing increased cellularity with a fascicular growth pattern and frequent extension into the subcutis. Here we describe a case of cellular fibrous histiocytoma showing repeated recurrence in a 36-year-old woman who initially presented with a 2-cm cutaneous tumor on her right elbow. Histopathologically, the first resected specimen demonstrated irregularly arranged collagen fibers mixed with scattered proliferating plump to spindle-shaped fibrohistiocytes. However, examination of the resected specimens obtained after recurrence showed that the cellularity had increased, the spindle-shaped cells showing monomorphic proliferation with a fascicular and storiform growth pattern extending into the subcutis, as well as an increase of Ki-67 positivity. Since the lesion showed repeated relapse within a short period, we performed wide-field resection of the tumor with a 3-cm margin. Currently, 48 months after surgery, there has been no local recurrence or metastasis, but continuous strict follow-up will be necessary.
- Published
- 2015
- Full Text
- View/download PDF
23. Transglutaminase
- Author
-
Cooper, A. J. L., Kim, S.-Y., Lajtha, Abel, editor, and Banik, Naren, editor
- Published
- 2007
- Full Text
- View/download PDF
24. Fibrin in Tissue Engineering
- Author
-
Eyrich, Daniela, Göpferich, Achim, Blunk, Torsten, Back, Nathan, editor, Cohen, Irun R., editor, Kritchevsky, David, editor, Lajtha, Abel, editor, Paoletti, Rodolfo, editor, and Fisher, John P., editor
- Published
- 2007
- Full Text
- View/download PDF
25. Tissue immunostaining for factor XIIIa in dermal dendrocytes of pityriasis alba skin lesions
- Author
-
Francisca Regina Oliveira Carneiro, Gabriela Borborema do Amaral, Maiana Darwich Mendes, and Juarez Antônio Simões Quaresma
- Subjects
Dermatitis, atopic ,Factor XIIIa ,Pityriasis ,Dermatology ,RL1-803 - Abstract
BACKGROUND: Pityriasis alba affects 1% of the world population and about 9.9% of the children in Brazil. However, its etiology remains uncertain. OBJECTIVE: The objective of the present study was to evaluate the immunoexpression of factor XIIIa in dermal dendrocytes of skin lesions of pityriasis alba. METHOD: Twenty patients with pityriasis alba and 20 patients with atopic dermatitis underwent biopsy. The dermal dendrocytes marked by factor XIIIa were counted by means of immunohistochemical analysis. RESULTS: The mean amount of dermal dendrocytes found in the patients with pityriasis alba was 2, whereas in the patients with atopic dermatitis it was 4, with a statistically significant difference between them. A cutoff point of 3 cells/square inch was established to differentiate pityriasis alba from atopic dermatitis, with 80% sensibility and 90% specificity. CONCLUSION: We believe that pityriasis alba and atopic dermatitis should be considered different clinical forms within the spectrum of atopic disease, in which sun radiation plays an important role by modulating the progression of the disease.
- Published
- 2014
- Full Text
- View/download PDF
26. Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury
- Author
-
Lauren G. Poole, Matthew J. Flick, Dafna J. Groeneveld, Anna K. Kopec, Kevin S. Baker, Asmita Pant, Holly Cline-Fedewa, and James P. Luyendyk
- Subjects
Male ,0301 basic medicine ,Immunology ,030204 cardiovascular system & hematology ,Fibrinogen ,Biochemistry ,Fibrin ,Polymerization ,Thrombosis and Hemostasis ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Thrombin ,medicine ,Animals ,Blood Coagulation ,Acetaminophen ,Mice, Knockout ,Factor XIII ,biology ,Cell Biology ,Hematology ,Analgesics, Non-Narcotic ,Molecular biology ,Mice, Inbred C57BL ,030104 developmental biology ,chemistry ,biology.protein ,Factor XIIIa ,Chemical and Drug Induced Liver Injury ,Peroxynitrite ,medicine.drug - Abstract
Intravascular fibrin clot formation follows a well-ordered series of reactions catalyzed by thrombin cleavage of fibrinogen leading to fibrin polymerization and cross-linking by factor XIIIa (FXIIIa). Extravascular fibrin(ogen) deposits are observed in injured tissues; however, the mechanisms regulating fibrin(ogen) polymerization and cross-linking in this setting are unclear. The objective of this study was to determine the mechanisms of fibrin polymerization and cross-linking in acute liver injury induced by acetaminophen (APAP) overdose. Hepatic fibrin(ogen) deposition and cross-linking were measured following APAP overdose in wild-type mice, mice lacking the catalytic subunit of FXIII (FXIII−/−), and in FibAEK mice, which express mutant fibrinogen insensitive to thrombin-mediated fibrin polymer formation. Hepatic fibrin(ogen) deposition was similar in APAP-challenged wild-type and FXIII−/− mice, yet cross-linking of hepatic fibrin(ogen) was dramatically reduced (>90%) by FXIII deficiency. Surprisingly, hepatic fibrin(ogen) deposition and cross-linking were only modestly reduced in APAP-challenged FibAEK mice, suggesting that in the APAP-injured liver fibrin polymerization is not strictly required for the extravascular deposition of cross-linked fibrin(ogen). We hypothesized that the oxidative environment in the injured liver, containing high levels of reactive mediators (eg, peroxynitrite), modifies fibrin(ogen) such that fibrin polymerization is impaired without impacting FXIII-mediated cross-linking. Notably, fibrin(ogen) modified with 3-nitrotyrosine adducts was identified in the APAP-injured liver. In biochemical assays, peroxynitrite inhibited thrombin-mediated fibrin polymerization in a concentration-dependent manner without affecting fibrin(ogen) cross-linking over time. These studies depict a unique pathology wherein thrombin-catalyzed fibrin polymerization is circumvented to allow tissue deposition and FXIII-dependent fibrin(ogen) cross-linking.
- Published
- 2021
27. Thromboelastographic study of fibrin clot and molecular basis of maximum clot firmness
- Author
-
V. I. Gryshchuk, Y. M. Stohnii, Chernyshenko Tm, V. O. Chernyshenko, S. I. Zhuk, O. I. Ivashchenko, K. P. Klymenko, O. M. Platonov, D S Korolova, O. P. Kostiuchenko, and I. V. Us
- Subjects
biology ,business.industry ,thromboelastography ,QD415-436 ,Biochemistry ,Fibrin ,factor xiiia ,maximum clot firmness ,biology.protein ,Medicine ,fibrinogen ,Maximum clot firmness ,business ,thrombosis ,Biomedical engineering - Abstract
Maximum clot firmness (MCF) is the main parameter of thromboelastography (TEG) reflecting the stability of a clot. In this work, we looked for markers that can influence the enhancement of MCF and detected molecular markers and blood clotting parameters that can be involved in such mechanisms. Blood samples of pregnant women with placental disorders were collected in the Kyiv Perinatal Center. TEG was performed on whole blood in EXTEM and INTEM tests. APTT, INR, fibrinogen concentration and platelet aggregation were measured using traditional laboratory approaches. D-dimer was detected in sandwich ELISA using monoclonal antibodies III-3B and II-4D. The relative cross-linking activity of factor XIIIa was measured by the direct quantification of the cross-linked γ-chain of fibrin using Western-Blotting with monoclonal antibody II-4D. D-dimer and fibrinogen concentrations, clotting time in the APTT test, INR and rate of platelet aggregation did not correlate with the MCF. However, we found positive correlations of MCF with factor XIIIa activity: 0.51 and 0.87 for EXTEM and INTEM, respectively. These data indicate that for normal and slightly increased fibrinogen concentrations, fibrin clot firmness will depend mostly on the activity of factor XIIIa. Thus the direct determination of factor XIIIa activity in blood plasma of patients can be relevant for predicting the risk of intravascular coagulation. Evaluation of the content and activity of individual clotting factors or other components of the coagulation system can be useful additions to the TEG diagnostics and should not be neglected.
- Published
- 2021
28. Uncommon cutaneous non-Langerhans cell histiocytosis arising from dermal dendritic cells in adults: a clinicopathological study of five cases
- Author
-
Nong, Lin, Ren, Yali, Dong, Ying, Li, Dong, Li, Xin, and Li, Ting
- Published
- 2020
- Full Text
- View/download PDF
29. Mesenchymal Markers (Nonhematopoietic)
- Author
-
Smoller, Bruce R., Damjanov, Ivan, editor, and Smoller, Bruce R.
- Published
- 2002
- Full Text
- View/download PDF
30. Rapid Hemostasis Resulting from the Synergism of Self-Assembling Short Peptide and O-Carboxymethyl Chitosan
- Author
-
Wenxin Wang, Xiaoting Peng, Yan Zhang, Jiaxi Chen, Ruirui Hao, Cuixia Chen, Yurong Zhao, Hai Xu, Tong Wang, and Xinglong Fan
- Subjects
chemistry.chemical_classification ,0303 health sciences ,Hemostatic Agent ,Materials science ,Biocompatibility ,Peptide ,02 engineering and technology ,021001 nanoscience & nanotechnology ,Chitosan ,03 medical and health sciences ,chemistry.chemical_compound ,chemistry ,Coagulation ,Hemostasis ,Self-healing hydrogels ,Biophysics ,General Materials Science ,Factor XIIIa ,0210 nano-technology ,030304 developmental biology - Abstract
The development of novel hemostatic agents with distinct modes of action from traditional ones remains a formidable challenge. Self-assembling peptide hydrogels have emerged as a new hemostatic material, not only because of their inherent biocompatibility and biodegradability but also their designability. Especially, rational molecular design can make peptides and their hydrogelation responsive to biological cues. In this study, we demonstrated that transglutaminase-catalyzed reactions not only occurred among designed short peptide I3QGK molecules but also between the peptide and a natural polysaccharide O-carboxymethyl chitosan. Because Factor XIII in the blood can rapidly convert into activated transglutaminase (Factor XIIIa) upon bleeding, these enzymatic reactions, together with the electrostatic attraction between the two hemostatic agents, induced a strong synergetic effect in promoting hydrogelation, blood coagulation, and platelet adhesion, eventually leading to rapid hemostasis. The study presents a promising strategy for developing alternative hemostatic materials and methods.
- Published
- 2020
31. The Effect of Activated FXIII, a Transglutaminase, on Vascular Smooth Muscle Cells
- Author
-
Réka, Bogáti, Éva, Katona, Amir H, Shemirani, Enikő, Balogh, Helga, Bárdos, Viktória, Jeney, and László, Muszbek
- Subjects
Thrombospondin 1 ,Transglutaminases ,Myocytes, Smooth Muscle ,Endothelial Cells ,Humans ,Collagen ,RNA, Messenger ,Factor XIIIa ,Muscle, Smooth, Vascular ,Plaque, Atherosclerotic - Abstract
Plasma factor XIII (pFXIII) is a heterotetramer of FXIII-A and FXIII-B subunits. The cellular form (cFXIII), a dimer of FXIII-A, is present in a number of cell types. Activated FXIII (FXIIIa), a transglutaminase, plays an important role in clot stabilization, wound healing, angiogenesis and maintenance of pregnancy. It has a direct effect on vascular endothelial cells and fibroblasts, which have been implicated in the development of atherosclerotic plaques. Our aim was to explore the effect of FXIIIa on human aortic smooth muscle cells (HAoSMCs), another major cell type in the atherosclerotic plaque. Osteoblastic transformation induced by Pi and Ca
- Published
- 2022
32. Juvenile Xanthogranuloma: A Comparative Immunohistochemical Study of Factor XIIIa, CD11c, and CD4
- Author
-
Behzad Salari and Louis P. Dehner
- Subjects
Male ,Histiocytosis, Non-Langerhans-Cell ,S100 Proteins ,Humans ,Female ,Dermatology ,General Medicine ,Child ,Factor XIIIa ,Xanthogranuloma, Juvenile ,Biomarkers ,Pathology and Forensic Medicine - Abstract
Juvenile xanthogranuloma is a group C and L non-Langerhans cell histiocytosis, and its cell of origin is still debatable. The expression of CD11c, a more recently described macrophage marker, and CD4 have not been studied comprehensively. This study aimed to expand immunophenotypic profile and hence our understanding of the origin of these lesions. The surgical pathology archive was searched for the cases with the pathologic diagnosis of "xanthogranuloma" from 1995 to 2019. Immunohistochemical (IHC) stains were performed for factor XIIIa, CD11c, and CD4. Morphologically, each lesion was classified into early classic, classic, or transitional subtypes. Seventy-seven cases were included with the median age of 7.8 years (male:female 1.3:1). Uniform positivity was noticed for CD4 (n = 77), CD68 (n = 37), CD163 (n = 5), and vimentin (n = 4) stains. Other stains included CD11c 75/77 (97.4%), factor XIIIa 71/76 (93.4%), S-100 protein 4/23 (17.4%), and CD1a 0/18 (0%). Despite insignificant association between morphologic subtype and main studied IHC stains, factor XIIIa reactivity was highest in transitional lesions and CD11c showed higher reactivity in early classic lesions. CD11c and CD4 are sensitive markers and showed promising results in the diagnosis of juvenile xanthogranuloma compared with factor XIIIa. Despite different reactivity of factor XIIIa and CD11c in various morphologic subtypes, such association was statistically insignificant.
- Published
- 2022
33. Dermatofibroma of the eyelid with monster cells.
- Author
-
Jakobiec, Frederick A., Tu, Yufei, Zakka, Fouad R., and Tong, Arthur K.F.
- Subjects
- *
DERMATOFIBROMA , *EYELID diseases , *MACROPHAGES , *BLOOD coagulation factor XIIIa , *LANGERHANS cells , *PATIENTS - Abstract
Dermatofibromas are most frequently encountered in women on the lower extremities, often after minor trauma. A recurrent lesion of the right lower eyelid developed in a 64-year-old woman. It harbored “monster cells” that were large, with either multiple nuclei or a single, large, convoluted, and hyperchromatic nucleus. The presence of these cells does not signify a malignant transformation. The background cells were either histiocytoid (many were adipophilin positive), spindled cells, or dendritiform cells without mitoses. Factor XIIIa, CD68, and CD163 immunostaining was positive, and a subpopulation of CD1a + Langerhans cells was intermixed. Facial and eyelid dermatofibromas are more likely to recur and deserve wider, tumor-free surgical margins. Their microscopic differential diagnosis includes a cellular scar, peripheral nerve tumor, atypical fibrous xanthoma, and dermatofibrosarcoma protuberans. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
34. Post-Translational Modifications of Platelet-Derived Amyloid Precursor Protein by Coagulation Factor XIII-A*
- Author
-
Lih Jiin Juang, Christian J. Kastrup, Wilfred A. Jefferies, Nima Mazinani, Woosuk S. Hur, and Lonna Munro
- Subjects
Blood Platelets ,Proteases ,Tissue transglutaminase ,030204 cardiovascular system & hematology ,Biochemistry ,Fibrin ,Amyloid beta-Protein Precursor ,03 medical and health sciences ,0302 clinical medicine ,mental disorders ,Amyloid precursor protein ,Animals ,Humans ,Platelet ,Platelet activation ,030304 developmental biology ,Mice, Knockout ,0303 health sciences ,biology ,Chemistry ,Thrombin ,Substrate (chemistry) ,Platelet Activation ,3. Good health ,Mice, Inbred C57BL ,biology.protein ,Factor XIIIa ,Protein Processing, Post-Translational ,Amyloid precursor protein secretase - Abstract
The physiological function of amyloid β precursor protein (APP) in platelets has remained elusive. Upon platelet activation, APP localizes to the platelet surface and is proteolytically processed by proteases to release various metabolites, including amyloid β (Aβ) and soluble APP. Synthetic Aβ is a substrate of activated coagulation factor XIII (FXIII-A*), a transglutaminase that is active both inside and on the surface of platelets. Here we tested if platelet APP and its fragments are covalently modified by FXIII-A*. Platelet-derived FXIII-A* and fibrin(ogen) bound to APP, and their bound fractions increased 7- and 11-fold upon platelet activation, respectively. The processing of platelet APP was enhanced when FXIII-A* was inhibited. Soluble APPβ was covalently cross-linked by FXIII-A*. This mechanism regulating APP processing is significant, because controlling the processing of APP, such as by inhibiting specific secretases that cleave APP, is a therapeutic target for Alzheimer's disease.
- Published
- 2020
35. Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
- Author
-
Srabani Kar, Madhusoodanan Mottamal, and Rami A. Al-Horani
- Subjects
anticoagulants ,Thrombin Time ,Organophosphonates ,010402 general chemistry ,01 natural sciences ,Factor XIa ,Factor IXa ,Thrombin ,Zymogen ,medicine ,Humans ,Factor IX ,Enzyme Assays ,Clotting factor ,Full Paper ,010405 organic chemistry ,Chemistry ,molecular modeling ,allosteric inhibitors ,Antithrombin ,General Chemistry ,Full Papers ,0104 chemical sciences ,Molecular Docking Simulation ,Biochemistry ,Zymogen activation ,phosphonate derivatives ,Partial Thromboplastin Time ,Factor XIIIa ,Allosteric Site ,medicine.drug ,Protein Binding - Abstract
The inhibition of factor XIa (FXIa) is a trending paradigm for the development of new generations of anticoagulants without a substantial risk of bleeding. In this report, we present the discovery of a benzyl tetra‐phosphonate derivative as a potent and selective inhibitor of human FXIa. Biochemical screening of four phosphonate/phosphate derivatives has led to the identification of the molecule that inhibited human FXIa with an IC50 value of ∼7.4 μM and a submaximal efficacy of ∼68 %. The inhibitor was at least 14‐fold more selective to FXIa over thrombin, factor IXa, factor Xa, and factor XIIIa. It also inhibited FXIa‐mediated activation of factor IX and prolonged the activated partial thromboplastin time of human plasma. In Michaelis‐Menten kinetics experiment, inhibitor 1 reduced the VMAX of FXIa hydrolysis of a chromogenic substrate without significantly affecting its KM suggesting an allosteric mechanism of inhibition. The inhibitor also disrupted the formation of FXIa – antithrombin complex and inhibited thrombin‐mediated and factor XIIa‐mediated formation of FXIa from its zymogen factor XI. Inhibitor 1 has been proposed to bind to or near the heparin/polyphosphate‐binding site in the catalytic domain of FXIa. Overall, inhibitor 1 is the first benzyl tetraphosphonate small molecule that allosterically inhibits human FXIa, blocks its physiological function, and prevents its zymogen activation by other clotting factors under in vitro conditions. Thus, we put forward benzyl tetra‐phosphonate 1 as a novel lead inhibitor of human FXIa to guide future efforts in the development of allosteric anticoagulants., The biochemical screening of four phosphonate/phosphate derivatives has led to the identification of a molecule that inhibited human FXIa with an IC50 value of ∼7.4 μM and a submaximal efficacy of ∼68 %. The inhibitor was at least 14‐fold more selective to FXIa over thrombin, factor IXa, factor Xa, and factor XIIIa.
- Published
- 2020
36. Mass-Encoded Reporters Reporting Proteolytic Activity from within the Extracellular Matrix
- Author
-
Marc Drießen, Stephanie Lamer, Lorenz Meinel, Andreas Schlosser, Tessa Lühmann, Sebastian Bölch, and Katharina Dodt
- Subjects
Tissue transglutaminase ,medicine.medical_treatment ,0206 medical engineering ,Biomedical Engineering ,Peptide ,02 engineering and technology ,Matrix metalloproteinase ,Biomaterials ,Extracellular matrix ,3D cell culture ,medicine ,Amino Acid Sequence ,Insulin-Like Growth Factor I ,Peptide sequence ,chemistry.chemical_classification ,Protease ,biology ,021001 nanoscience & nanotechnology ,020601 biomedical engineering ,Matrix Metalloproteinases ,Extracellular Matrix ,Cell biology ,chemistry ,Proteolysis ,biology.protein ,Factor XIIIa ,0210 nano-technology - Abstract
Reporting matrix metalloproteinase (MMP) activity directly from the extracellular matrix (ECM) may provide critical insights to better characterize 2D and 3D cell culture model systems of inflammatory diseases and potentially leverage in vivo diagnosis. In this proof-of-concept study, we designed MMP-sensors, which were covalently linked onto the ECM by co-administration of the activated transglutaminase factor XIIIa (FXIIIa). Elements of the featured MMP-sensors are the D-domain of insulin-like growth factor I (IGF-I) through which co-administered FXIIIa covalently links the sensor to the ECM followed by an MMP sensitive peptide sequence and locally reporting on MMP activity, an isotopically labeled mass tag encoding for protease activity, and an affinity tag facilitating purification from fluids. All sensors come in identical pairs, other than the MMP sensitive peptide sequence, which is synthesized with l-amino acids or d-amino acids, the latter serving as internal standard. As a proof of concept for multiplexing, we successfully profiled two MMP-sensors with different MMP sensitive peptide sequences reporting MMP activity directly from an engineered 3D ECM. Future use may include covalently ECM bound diagnostic depots reporting MMP activity from inflamed tissues.
- Published
- 2020
37. The Structural–Functional Damage of Fibrinogen Oxidized by Hydrogen Peroxide
- Author
-
M. A. Rosenfeld, Anna E. Bugrova, V. L. Kononenko, Maria I. Indeykina, A.S. Kononikhin, E. N. Nikolaev, L. V. Yurina, and A. D. Vasilyeva
- Subjects
Microrheology ,Plasmin ,Biophysics ,Oxidative phosphorylation ,Fibrinogen ,Biochemistry ,Fibrin ,Structure-Activity Relationship ,03 medical and health sciences ,Hydrolysis ,chemistry.chemical_compound ,medicine ,Humans ,Fibrinolysin ,Hydrogen peroxide ,030304 developmental biology ,0303 health sciences ,biology ,Chemistry ,030302 biochemistry & molecular biology ,Hydrogen Peroxide ,General Chemistry ,General Medicine ,Oxidants ,biology.protein ,Factor XIIIa ,Oxidation-Reduction ,medicine.drug - Abstract
The effect of peroxide-induced oxidation of fibrinogen on modification of its primary structure and functional properties was investigated. The oxidation sites were shown to be Met, Trp, and His residues. Using the DLS method, it was found that the oxidative modification of fibrinogen results in the change of microrheological characteristics of fibrin network. The fibrinogen oxidation diminishes its tolerance to plasmin hydrolysis and deteriorates the factor XIIIa ability to stabilize the fibrin gel.
- Published
- 2020
38. The factor XIII‐A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations
- Author
-
Zsuzsa Bagoly, Alisa S. Wolberg, László Muszbek, Noémi Tóth, and Sravya Kattula
- Subjects
medicine.medical_specialty ,030204 cardiovascular system & hematology ,Fibrinogen ,Article ,Fibrin ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Platelet ,Whole blood ,Prothrombin time ,Polymorphism, Genetic ,Factor XIII ,medicine.diagnostic_test ,biology ,Chemistry ,Thrombosis ,Hematology ,medicine.disease ,Venous thrombosis ,Red blood cell ,medicine.anatomical_structure ,Endocrinology ,biology.protein ,Factor XIIIa ,circulatory and respiratory physiology ,medicine.drug - Abstract
BACKGROUND: Factor XIII (FXIII) promotes fibrin crosslinking and red blood cell (RBC) retention in clots. The FXIII-A polymorphism, Val34Leu, is associated with protection against venous thrombosis. This effect is hypothesized to result from fibrinogen concentration-dependent changes in fibrin structure. Effects of the FXIII-A Val34Leu polymorphism in whole blood clots have not been investigated. AIM: Characterize effects of FXIII-A Val34Leu polymorphism and fibrinogen on whole blood clots. METHODS: We isolated platelet-poor plasmas from human donors (FXIII(Val/Val), FXIII(Val/Leu), FXIII(Leu/Leu)), reconstituted plasmas with platelets and RBCs, and triggered clotting. We assessed contributions of gender, age, clotting times, thrombin generation, FXIII activity, FXIII-A Val34Leu polymorphism, and fibrinogen to clot mass. We also reconstituted FXIII-depleted plasma with platelets, RBCs, and purified FXIII(Val/Val) or FXIII(Leu/Leu), varied fibrinogen, and characterized effects on clot mass. RESULTS: Clot mass was associated with age, fibrinogen, prothrombin time, and thrombin generation. Clots reconstituted with plasmas from individuals with FXIII-A(Val/Val) and FXIII-A(Val/Leu) did not differ in mass from clots with FXIII-A(Leu/Leu). However, clots containing a 34Val allele demonstrated a fibrinogen concentration-dependent increase in mass, whereas clots with homozygous 34Leu did not. In plasmas with high fibrinogen, mass was higher for clots with 34Val alleles compared to clots with homozygous 34Leu. In clots reconstituted with purified FXIII, increasing fibrinogen enhanced clot mass in the presence of 34Val, but decreased mass in the presence of 34Leu. CONCLUSIONS: FXIII 34Leu mitigates the effect of elevated fibrinogen on whole blood clot mass. The Val34Leu polymorphism may protect against venous thrombosis by reducing clot mass.
- Published
- 2020
39. Scleromyxedema histopathologically mimicking hypercellular fibrous papules (angiofibomas): Case report of an unusual histopathological presentation
- Author
-
Viktoryia Kazlouskaya, Edward Heilman, and Neelam Khan
- Subjects
medicine.medical_specialty ,Pathology ,Histology ,business.industry ,CD68 ,Mucin ,Dermatology ,Angiofibroma ,medicine.disease ,Angiofibromas ,Colloidal iron ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Scleromyxedema ,medicine ,Histopathology ,Factor XIIIa ,business - Abstract
Scleromyxedema (SMX) is an inflammatory condition of unknown etiology strongly associated with monoclonal gammopathy. Classical histopathology of SMX is characterized with the triad of diffuse mucin deposits, increased amount of collagen, and presence of stellate fibroblasts. Herein, we report an unusual histopathological variant of SMX in a 41-year-old female with lesions of the nose histopathologically mimicking cellular angiofibromas. The dome-shaped papules were characterized by increased collagen bundles and fascicles of spindle cells. Widened vessels were seen at the periphery of the proliferation. Cells expressed CD68. Factor XIIIa was expressed only by dendritic cells. The mucin was highlighted with colloidal iron. In sum, we draw attention to this unusual variant of SMX, which should be suspected in a setting of multiple "angiofibromas/fibrous papules" on the face with presence of mucin.
- Published
- 2020
40. Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1
- Author
-
Ilaria De Simone, Constance C. F. M. J. Baaten, Martine Jandrot-Perrus, Jonathan M. Gibbins, Hugo ten Cate, Johan W. M. Heemskerk, Chris I. Jones, Paola E. J. van der Meijden, Biochemie, RS: Carim - B03 Cell biochemistry of thrombosis and haemostasis, RS: Carim - B04 Clinical thrombosis and Haemostasis, MUMC+: HVC Trombosezorg (8), and MUMC+: HVC Pieken Trombose (9)
- Subjects
Blood Platelets ,Platelet Aggregation ,Hirudins/metabolism ,Phosphatidylserines ,Platelet Glycoprotein GPIIb-IIIa Complex ,Platelet Membrane Glycoproteins ,Platelet Glycoprotein GPIIb-IIIa Complex/metabolism ,Syk Kinase/metabolism ,Fibrin/metabolism ,Catalysis ,Inorganic Chemistry ,Phosphatidylserines/metabolism ,Protein C/metabolism ,glycoprotein VI ,protease-activated receptor 1 ,platelet activation ,coagulation ,coagulation factor XIIIa ,activated protein C ,Syk Kinase ,Receptor, PAR-1 ,PAR-1/metabolism ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,Receptor, PAR-1/metabolism ,Fibrin ,Thrombin/metabolism ,Organic Chemistry ,Thrombin ,General Medicine ,Hirudins ,Platelet Activation ,Platelet Membrane Glycoproteins/metabolism ,Computer Science Applications ,Factor XIIIa/metabolism ,P-Selectin ,P-Selectin/metabolism ,Blood Platelets/metabolism ,Factor XIIIa ,Protein C ,Receptor - Abstract
International journal of molecular sciences 23(18), 10203 (2022). doi:10.3390/ijms231810203 special issue: "Special Issue "Molecular Mechanisms of Hemostasis, Thrombosis and Thrombo-Inflammation 2.0" / Special Issue Editors: Dr. Kerstin Jurk, Guest Editor; Dr. Marijke J.E. Kuijpers, Guest Editor; Prof. Dr. Johan W. M. Heemskerk, Guest Editor", Published by Molecular Diversity Preservation International, Basel
- Published
- 2022
- Full Text
- View/download PDF
41. Gastric Calcifying Fibrous Tumor: A Very Rare Case Report
- Author
-
T. Vasilakaki, E. Skafida, A. Tsavari, E. Arkoumani, K. Koulia, D. Myoteri, X. Grammatoglou, E. Moustou, N. Firfiris, and D. Zisis
- Subjects
Calcifying fibrous tumor ,Stomach ,Factor XIIIa ,Mesenchymal tumor ,Endoscopic ultrasound ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Calcifying fibrous tumor is a very rare benign mesenchymal tumor which shows a predilection for soft tissue, mesentery and peritoneum. Up to date only 7 cases have been reported in the literature confined to the gastric wall. We report a rare case of a calcifying fibrous tumor of the stomach in a 60-year-old man who presented with dyspepsia, flatulence and feeling weight. A clinical and laboratory investigation was performed with normal results. Gastroscopy revealed a bulge in the gastric body measuring 1 cm with normal overlying mucosa, and mucosal biopsies showed chronic gastritis. Endoscopic ultrasound of the gastric bulge showed a 1 × 0.8 cm hypoechoic lesion involving the gastric wall. After the above finding a wedge resection of the stomach was performed. Microscopically the lesion consisted of well-circumscribed hypocellular hyalinized fibrosclerotic tissue with lympoplasmatic infiltrates, lymphoid aggregates and psammomatous calcifications. Lesional cells were positive for vimentin and factor XIII and negative for actin, desmin, S100p, CD117, CD34, CD31 and ALK-1. The lesion involved the muscularis propria with variable submucosal extension. Calcifying fibrous tumor has shown an excellent prognosis with recurrences being rare and showing the same morphology as the primary lesion.
- Published
- 2012
- Full Text
- View/download PDF
42. Immunoelectron microscopy study of superficial skin nerves in drug-induced acute urticaria Estudo de microscopia imunoeletrônica dos nervos superficiais da pele na urticária aguda induzida por medicamentos
- Author
-
Paulo Ricardo Criado, Roberta Fachini Jardim Criado, Cleusa F.H. Takakura, Carla Pagliari, Mirian Nacagami Sotto, and Cidia Vasconcellos
- Subjects
fator XIIIa ,mastócitos ,neurônios ,triptases ,urticária ,factor XIIIa ,mast cells ,neurons ,tryptases ,urticaria ,Dermatology ,RL1-803 - Abstract
BACKGROUND: Few studies have evaluated the ultrastructure of the superficial skin nerves in urticaria. OBJECTIVE: The objective of this study was to describe findings in superficial skin nerves in cases of drug-induced acute urticaria. METHODS: Seven patients with drug-induced acute urticaria were included in the study. Skin biopsies were obtained from the urticarial lesion and from the apparently normal skin. The 14 fragments collected were processed for immunogold electron microscopy using single stains for antitryptase and anti-FXIIIa antibodies, as well as double immunogold labeling for both. RESULTS: Some sections showed mast cells in the process of degranulation. Following double immunogold staining, 10 nm (FXIIIa) and 15 nm (Tryptase) gold particles were found together throughout the granules in mast cells, indicating that tryptase and FXIIIa are located inside each one of the granules of these cells. Interestingly, we found strong evidence of the presence of tryptase and factor XIIIa in the superficial skin nerves of these patients, both in cases of urticarial lesions (wheals) and in the apparently normal skin. CONCLUSIONS: Tryptase and FXIIIa are present in the superficial nerves of the skin in drug-induced acute urticaria. This is the first report of tryptase and FXIIIa expression in the superficial skin nerves of patients with urticaria. Tryptase may be participating in neural activation in these patients, while FXIIIa may be present in the nerves to guarantee the functional integrity of structures.FUNDAMENTOS: Poucos autores têm estudado a ultraestrutura dos nervos superficiais na urticária. OBJETIVO: Descrever os achados nos nervos cutâneos superficiais em casos de urticária aguda induzida por medicamentos. MÉTODOS: Sete pacientes com urticária aguda induzida por medicamentos foram incluídos no estudo. Foram obtidas biopsias da pele da lesão urticariforme e da pele aparentemente normal. Os 14 fragmentos coletados foram processados usando imunomarcação com ouro para anticorpos anti-triptase e anti-FXIIIa separadamente, além da dupla imunomarcação com ambos anticorpos. A seguir as amostras foram submetidas à análise por microscopia imunoeletrônica. RESULTADOS: Alguns cortes demonstraram mastócitos em processo de degranulação. Após a imunomarcação dupla, partículas de ouro de 10 nm (FXIIIa) e partículas de ouro de 15 nm (Triptase) apresentavam-se juntas em grânulos de mastócitos indicando que a triptase e o FXIIIa se localizam dentro de cada um dos grânulos dessas células. Curiosamente, foi encontrada uma forte evidência da presença da triptase e do fator XIIIa nos nervos superficiais dos pacientes avaliados, tanto em lesões urticadas, como na pele aparentemente normal. CONCLUSÕES: A triptase e o FXIIIa estão presentes nos nervos superficiais da pele na urticária aguda medicamentosa. Este é o primeiro relato da expressão de triptase e de FXIIIa nos nervos superficiais na urticária. A triptase poderia estar participando da ativação neural nos pacientes estudados. O FXIIIa poderia estar presente nos nervos, com a finalidade de manter a integridade funcional dessas estruturas.
- Published
- 2012
- Full Text
- View/download PDF
43. Mast cell-derived factor XIIIA contributes to sexual dimorphic defense against group B streptococcal infections
- Author
-
Adrian M. Piliponsky, Kavita Sharma, Phoenicia Quach, Alyssa Brokaw, Shayla Nguyen, Austyn Orvis, Siddhartha S. Saha, Nyssa Becker Samanas, Ravin Seepersaud, Yu Ping Tang, Emily Mackey, Gauri Bhise, Claire Gendrin, Anna Furuta, Albert J. Seo, Eric Guga, Irina Miralda, Michelle Coleman, Erin L. Sweeney, Charlotte A. Bäuml, Diana Imhof, Jessica M. Snyder, Adam J. Moeser, and Lakshmi Rajagopal
- Subjects
Male ,Fibrin ,Transglutaminases ,General Medicine ,Fibronectins ,Streptococcus agalactiae ,Mice ,Streptococcal Infections ,Androgens ,Animals ,Humans ,Female ,Mast Cells ,Factor XIIIa - Abstract
Invasive bacterial infections remain a major cause of human morbidity. Group B streptococcus (GBS) are Gram-positive bacteria that cause invasive infections in humans. Here, we show that factor XIIIA-deficient (FXIIIA-deficient) female mice exhibited significantly increased susceptibility to GBS infections. Additionally, female WT mice had increased levels of FXIIIA and were more resistant to GBS infection compared with isogenic male mice. We observed that administration of exogenous FXIIIA to male mice increased host resistance to GBS infection. Conversely, administration of a FXIIIA transglutaminase inhibitor to female mice decreased host resistance to GBS infection. Interestingly, male gonadectomized mice exhibited decreased sensitivity to GBS infection, suggesting a role for gonadal androgens in host susceptibility. FXIIIA promoted GBS entrapment within fibrin clots by crosslinking fibronectin with ScpB, a fibronectin-binding GBS surface protein. Thus, ScpB-deficient GBS exhibited decreased entrapment within fibrin clots in vitro and increased dissemination during systemic infections. Finally, using mice in which FXIIIA expression was depleted in mast cells, we observed that mast cell-derived FXIIIA contributes to host defense against GBS infection. Our studies provide insights into the effects of sexual dimorphism and mast cells on FXIIIA expression and its interactions with GBS adhesins that mediate bacterial dissemination and pathogenesis.
- Published
- 2021
44. CD34+ Hematopoietic Progenitors from Human Cord Blood Differentiate Along two Independent Dendritic Cell Pathways in Response to GM-CSF+TNFα
- Author
-
Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., de Saint-Vis, B., Dezutter-Dambuyant, C., Jacquet, C., Schmitt, D., Banchereau, J., and Ricciardi-Castagnoli, Paola, editor
- Published
- 1997
- Full Text
- View/download PDF
45. Interstitial and Langerhans' dendritic cells in chronic periodontitis and gingivitis
- Author
-
Patricia Ramos Cury, Cristiane Furuse, Ana Elisa Amaro Rodrigues, José Alexandre Barbuto, Cavalcanti de Araújo, and Ney Soares de Araújo
- Subjects
Periodontitis ,Gingivitis ,Dendritic cells ,CD1a ,Factor XIIIa ,Dentistry ,RK1-715 - Abstract
The aim of the present study was to compare quantitatively the distribution of dendritic cell subpopulations in chronic periodontitis and gingivitis. Fourteen biopsies from patients with chronic periodontitis and fifteen from patients with gingivitis were studied. An immunoperoxidase technique was used to quantify the number of Langerhans' cells (CD1a) and interstitial dendritic cells (factor XIIIa) in the oral and sulcular and junctional/pocket epithelia and in the lamina propria. A greater number of factor XIIIa+ dendritic cells in the lamina propria and CD1a+ dendritic cells in the oral epithelium were observed in gingivitis compared to the periodontitis group (p = 0.05). In the sulcular and junctional/pocket epithelia and in the lamina propria, the number of CD1a+ dendritic cells was similar in the gingivitis and periodontitis groups. In conclusion, the number of Langerhans' cells in the oral epithelium and interstitial dendritic cells in the lamina propria is increased in gingivitis compared to periodontitis, which may contribute to the different pattern of host response in these diseases.
- Published
- 2008
- Full Text
- View/download PDF
46. Cell Trafficking Networks in Cutaneous T Cell Lymphoma
- Author
-
Fivenson, David P., Nickoloff, Brian J., Lambert, W. Clark, editor, Giannotti, Benvenuto, editor, and van Vloten, Willem A., editor
- Published
- 1994
- Full Text
- View/download PDF
47. Dendritic Cell Activation in Leprosy Using CD1a and Factor XIIIa Markers.
- Author
-
K K, S S, and K S
- Abstract
Background: Leprosy is manifested in varied forms based on the immune status of the patient giving rise to the polar and borderline spectrum of tuberculoid (TT) and lepromatous leprosy (LL). The present study was conducted to assess the macrophage activation in the spectrum of leprosy using CD1a and Factor XIIIa immunohistochemical markers and to correlate the macrophage expression with the morphological spectrum and bacillary index., Methodology: The present study was an observational study., Results: The present study consisted of 40 biopsy-proven leprosy cases, in which a majority were males, and the most common age group was 20-40 years. The most common type encountered was borderline tuberculoid (BT) leprosy. Expression of epidermal dendritic cells and intensity of staining by CD1a was higher in TT (seven of 10 cases (70%)) when compared to LL (one of three cases (33%)). Similarly, Factor XIIIa showed higher expression of dermal dendritic cells in 90% of TT when compared to LL which was seen in 66%., Conclusion: The increased number and strong intensity of dendritic cells in the tuberculoid spectrum may indirectly indicate macrophage activation and possibly account for the low bacillary index., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, K et al.)
- Published
- 2023
- Full Text
- View/download PDF
48. Macrophages CD163+ and Factor XIIIa+ Provide a First-Line Defence against Proliferative Verrucous Leukoplakia Antigens.
- Author
-
Palaçon MP, de Oliveira Barbeiro C, Fernandes D, Biancardi MR, Silveira HA, Ferrisse TM, León JE, Kujan O, and Bufalino A
- Subjects
- Humans, Interleukin-3 Receptor alpha Subunit, Leukoplakia, Oral, Macrophages pathology, Cell Transformation, Neoplastic pathology, Factor XIIIa, Mouth Neoplasms pathology
- Abstract
This study aimed to evaluate the density of the dendritic cells (DCs) and macrophages in oral leukoplakia (OL) and proliferative verrucous leukoplakia (PVL) by immunohistochemical analysis. We analysed paraffined tissue samples of PVL ( n = 27), OL ( n = 20), and inflammatory fibrous hyperplasia ( n = 20) as the control group using the immunomarkers for DCs (CD1a, CD207, CD83, CD208 and CD123) and macrophages (CD68, CD163, FXIIIa and CD209). A quantitative analysis of positive cells in the epithelial and subepithelial areas was determined. Our results showed a reduction in CD208+ cells in the subepithelial area of the OL and PVL compared to the control. Additionally, we found a higher density of FXIIIa+ and CD163+ cells in the subepithelial area in PVL compared to the OL and control. Four-way MANOVA revealed a relationship between increased CD123+ cell density in the subepithelial area of "high-risk" samples regardless of disease. Macrophages provide the first line of defence against PVL antigens, suggesting a distinct pattern of innate immune system activation in PVL compared to OL, which may contribute to the complexity and the high rate of malignant transformation in the PVL.
- Published
- 2023
- Full Text
- View/download PDF
49. Perfil histopatológico e imuno-histoquímico da leishmaniose tegumentar americana com ênfase nos dendrócitos dérmicos FXIIIa+ Histopathological and immunohistochemical profile of the American cutaneous leishmaniasis with emphasis on FXIIIa+ dermal dendrocytes
- Author
-
Maria Luisa Duarte and Mayra Carrijo Rochael
- Subjects
Auto-imunidade ,Células dendríticas ,Fator XIIIa ,Leishmaniose cutânea ,Autoimmunity ,Cutaneous leishmaniasis ,Dendritic cells ,Factor XIIIa ,Dermatology ,RL1-803 - Abstract
FUNDAMENTOS: Leishmaniose tegumentar é doença parasitária infecciosa que apresenta aspectos imunológicos relevantes. OBJETIVO: Estudar a histopatologia e aspectos imuno-histoquímicos de 21 biópsias de leishmaniose tegumentar. MÉTODOS: Anticorpo policlonal anti-Leishmania foi utilizado para identificação das leishmânias. A classificação histopatológica adotada foi em grupos padrões de I a V. Foram analisados os dendrócitos dérmicos FXIIIa+, células de Langerhans CD1a+, macrófagos CD68+, linfócitos B CD20+ e T CD3+. As células FXIIIa+ foram quantificadas na derme papilar e comparadas a peles normais obtidas de área não exposta à luz solar, sendo o número de células FXIIIa+ avaliado estatisticamente através do teste de Mann-Whitney. As demais células foram contadas semiquantitativamente. RESULTADOS: Entre os grupos histopatológicos, predominaram os I e II. Não houve diferença estatisticamente significante (p=0,157) entre o número de células FXIIIa+ na leishmaniose e na pele normal. Não foi observada diferença si ificante entre a presença das células CD1a+, CD68+, CD20+ e CD3+, quando comparadas entre si ou com as células FXIIIa+. CONCLUSÃO: Não houve diferença no número de células dendríticas FXIIIa+ entre a leishmaniose e pele normal. No entanto, sugere-se que mais estudos sejam necessários para se entender o papel dessas células na leishmaniose.BACKGROUND: Mucocutaneous leishmaniasis is a parasitic infectious disease with relevant immunological aspects. OBJECTIVE: To study the histopathological and immunohistochemical aspects of 21 leishmaniasis tegumentary biopsies. METHODS: Polyclonal anti-Leishmania antibody was used to confirm the presence of Leishmania amastigotes. Histopathological classification comprised I-V standard groups. The immunopathological pattern was evaluated as to the presence of FXIIIa+ dermal dendrocytes, CD1a+ Langerhans cells, CD68+ macrophages, CD20+ B lymphocytes, and CD3+ T lymphocytes. The FXIIIa+ cells were quantified and compared to specimens of normal skin obtained from unexposed areas. The other cells were counted in a semi-quantitative way. The number of FXIIIa+ cells was statistically analyzed using the Mann-Whitney test. RESULTS: Among the histopathological groups, I and II standards prevailed. The FXIIIa+ cells were observed for different aspects and compared to normal skin, without significant statistical differences (p = 0.157). There was no relation between the amount of CD1a+, CD68+, CD20+ and CD3+ cells when compared to each other or to FXIIIa+ cells. CONCLUSION: There was no difference between the number of FXIIIa+ cells in leishmaniasis and in normal skin. However, more studies are needed in order to understand the role of FXIIIa+ cells in leishmaniasis.
- Published
- 2006
- Full Text
- View/download PDF
50. Nuclear factor XIIIa staining (clone AC-1A1 mouse monoclonal) is a sensitive and specific marker to discriminate sebaceous proliferations from other cutaneous clear cell neoplasms.
- Author
-
Uhlenhake, Elizabeth E., Clark, Lindsey N., Smoller, Bruce R., Shalin, Sara C., and Gardner, Jerad M.
- Subjects
- *
BLOOD coagulation factor XIIIa , *CELL proliferation , *CELL populations , *CELL division , *CELL growth - Abstract
Sebaceous carcinoma is a rare but serious malignancy that may be difficult to diagnose when poorly differentiated. Other epithelial tumors with clear cell change may mimic sebaceous carcinoma. Few useful or specific immunohistochemical markers for sebaceous differentiation are available. Nuclear staining with factor XIIIa (clone AC-1A1) was recently found to be a highly sensitive marker of sebaceous differentiation. We evaluated nuclear factor XIIIa (AC-1A1) staining in sebaceous neoplasms vs. other cutaneous clear cell tumors. We stained 27 sebaceous proliferations: sebaceous hyperplasia (7), sebaceous adenoma (8), sebaceoma (5), sebaceous carcinoma (7). We also stained 67 tumors with clear cell change: basal cell carcinoma (8), squamous cell carcinoma (8), hidradenoma (7), desmoplastic trichilemmoma (2), trichilemmoma (10), trichilemmal carcinoma (3), clear cell acanthoma (9), atypical fibroxanthoma (1), syringoma (8), trichoepithelioma (1), metastatic renal cell carcinoma (2), and nevi with balloon cell change (8). Nuclear factor XIIIa (AC-1A1) staining was present in 100% of sebaceous proliferations; 96% displayed strong staining. Non-sebaceous clear cell tumors were negative or only weakly positive with factor XIIIa (AC-1A1) in 95.5%; only 4.5% showed strong staining. This suggests that strong nuclear factor XIIIa (AC-1A1) staining is a sensitive and specific marker of sebaceous neoplasms vs. other clear cell tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.